The landscape of sleep apnea treatment has changed more in the past year than in the previous decade. For nearly 40 years, CPAP machines were basically the only real option. But 2024 and 2025 have brought genuine alternatives that are changing how we think about treating this condition.
Key Takeaway
- The FDA approved the first medication specifically for sleep apnea (Zepbound) in December 2024, offering a pharmaceutical option for patients with obesity
- New implantable devices like Inspire V and Genio provide mask-free solutions with 72% success rates
- AD109, an investigational oral medication, showed 56% reduction in sleep apnea events across all severity levels in Phase 3 trials
- Daytime neuromuscular stimulation (eXciteOSA) and improved oral appliances expand non-invasive options
- These innovations address the persistent CPAP adherence crisis, where 40-60% of patients struggle with long-term use
Why We Need Better Sleep Apnea Solutions
Sleep apnea affects approximately one billion people worldwide, with about 54 million adults in the United States alone. The numbers are staggering when you consider that 32% of American adults aged 20 and older live with some degree of this condition.
This goes far beyond just snoring or feeling tired. Untreated sleep apnea significantly increases your risk of serious cardiovascular problems including:
- Hypertension
- Heart attack
- Stroke
- Cognitive decline and memory issues
- Motor vehicle accidents due to daytime sleepiness
For nearly 40 years, CPAP therapy has been the gold standard treatment. While it works well when used consistently, the reality is that between 30% and 60% of patients can't tolerate it long term. Research shows that after 24 months, only 45% of patients achieve high adherence, defined as using CPAP at least four hours per night on 70% of nights.
The reasons people abandon CPAP make sense:
- The pressurized air feels uncomfortable during exhalation
- Masks cause claustrophobic reactions and skin irritation
- The equipment is noisy and disrupts bed partners
- Some patients experience nasal congestion, air swallowing, and bloating
- About 50% of people prescribed CPAP simply cannot tolerate it and stop using it altogether
This adherence crisis has driven substantial investment in developing alternatives that maintain effectiveness while addressing the fundamental limitations that make CPAP unbearable for so many people.
The First FDA-Approved Medication for Sleep Apnea
In December 2024, the FDA made history by approving Zepbound (tirzepatide) as the first prescription medication specifically indicated for moderate to severe obstructive sleep apnea in adults with obesity.
Tirzepatide works as a dual-agonist medication, activating both GLP-1 and glucose-dependent insulinotropic polypeptide receptors. These are hormones your intestine secretes that reduce appetite and food intake. By promoting weight loss, tirzepatide reduces the excess tissue around your neck and upper airway that contributes to obstruction during sleep.
The approval was based on the SURMOUNT-OSA trial, which enrolled 469 adults without type 2 diabetes. Participants received either 10 or 15 milligrams of tirzepatide or placebo once weekly for 52 weeks. The results were impressive:
- About 50% of treated participants achieved complete remission or mild sleep apnea with resolved symptoms
- About 22% reached complete disease control with fewer than five apneic events per hour
- The magnitude of improvement correlated directly with the amount of weight lost
However, tirzepatide comes with important limitations:
- The approval restricts use to patients with documented obesity
- The therapeutic response takes time, requiring weeks to months for meaningful weight loss
- Side effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort
- It carries a boxed warning about potential thyroid tumors based on animal studies
- Cost runs approximately $1,086 for a 28-day supply (roughly $14,000 annually)
While insurance coverage exists, many plans hadn't updated their guidelines for the sleep apnea indication by early 2025, requiring appeals and physician documentation to access the medication.
Despite these limitations, tirzepatide represents genuine progress. It addresses a long-standing gap by offering a pharmacological option that targets the metabolic underpinnings of sleep apnea in certain populations.
AD109: A Game-Changing Oral Medication
While tirzepatide works through weight loss, AD109 takes an entirely different approach by targeting the neuromuscular dysfunction that causes airway collapse. This investigational medication represents the first oral therapy specifically designed to address the root neuromuscular cause of obstructive sleep apnea.
AD109 combines two distinct pharmacological agents:
- Aroxybutynin (a novel antimuscarinic compound)
- Atomoxetine (a selective norepinephrine reuptake inhibitor)
Atomoxetine, originally FDA-approved for ADHD in 2002, increases levels of norepinephrine by blocking its reuptake. Norepinephrine is an excitatory neurotransmitter that declines during sleep, contributing to loss of tone in upper airway muscles. By maintaining higher norepinephrine levels, atomoxetine helps preserve muscle tone.
Aroxybutynin blocks muscarinic acetylcholine receptors, preventing acetylcholine-mediated inhibition of the hypoglossal nerve. This effectively increases genioglossus muscle tone during sleep, keeping the tongue from collapsing backward into the airway.
Two large Phase 3 trials published results in 2025:
The SynAIRgy trial enrolled 646 participants with mild, moderate, and severe sleep apnea across all weight classes. Results showed a 56% reduction in apnea-hypopnea index compared to placebo, with 22% of treated patients achieving complete disease control (AHI less than 5 events per hour).
The LunAIRo trial enrolled 660 participants across 64 U.S. centers, specifically including patients intolerant of or refusing CPAP therapy. The trial demonstrated a 46.8% reduction in AHI from baseline compared to 6.8% reduction in placebo, with sustained efficacy through 51 weeks.
What makes AD109 distinctive:
- Immediate efficacy without requiring sustained weight loss
- Applicability across all severity levels regardless of weight
- Utility for both obese and non-obese populations
- Effects evident by 26 weeks, considerably faster than tirzepatide's timeline
The most common side effects were dry mouth, insomnia, and nausea – typically mild to moderate in severity with no serious treatment-related adverse events reported.
Apnimed plans to submit a new drug application to the FDA in early 2026, potentially making AD109 available within 18 to 24 months. If approved, it would become the first oral pharmaceutical therapy specifically targeting neuromuscular dysfunction in sleep apnea, offering patients a simple once-nightly pill requiring no device, mask, or surgery.
Implantable Neurostimulation: From Inspire to Genio
Upper airway stimulation using implantable hypoglossal nerve stimulation has fundamentally altered the treatment landscape for patients unable to tolerate CPAP. The Inspire system received FDA approval in 2014 and has become the most extensively validated alternative to CPAP therapy.
How Inspire Works
The Inspire system functions as what doctors call a "pacemaker for the tongue." Surgeons implant a small generator beneath the collarbone, position a breathing-sensing lead between chest muscles, and attach a stimulation lead to the hypoglossal nerve branch that controls tongue movement.
When you activate the device with a handheld remote before sleep, the system monitors your breathing throughout the night. When it detects airway obstruction, it delivers precisely calibrated electrical pulses that stimulate the hypoglossal nerve, triggering gentle tongue muscle contraction that pulls the tongue forward and opens the obstructed airway.
The Results
The landmark STAR trial included 126 patients with moderate to severe sleep apnea who had difficulty with CPAP. Results demonstrated:
- 68% reduction in apnea-hypopnea index from 29.3 events per hour to 9.0 events per hour at 12 months
- About 66% of subjects achieved at least a 50% reduction in AHI with residual AHI below 20 events per hour
Long-term follow-up studies confirmed maintenance of therapeutic efficacy at three and five years post-implantation. A comprehensive 2020 analysis involving 350 patients across 12 studies found a surgical success rate of 72.4% at 12 months, maintained at 75% at 60-month follow-up.
More than 100,000 patients have pursued Inspire therapy. Patient satisfaction is high:
- About 80% of bed partners report no snoring or only soft snoring
- Approximately 89% of patients recommend the therapy to others
- Quality of life improvements are substantial
The Next Generation: Inspire V and Genio
In August 2024, the FDA approved Inspire V, the next-generation device featuring:
- Simplified architecture with only two hardware components instead of three
- More advanced programming capabilities
- A considerably shortened surgical procedure (approximately 20 minutes briefer than prior generations)
Then in August 2025, the FDA approved the Genio system from Nyxoah, representing the first bilateral hypoglossal nerve stimulation device. Genio introduces significant innovations:
- Battery-free, leadless implant design activated by an external wearable device worn during sleep
- Compatibility with both 1.5T and 3T MRI scanners
- Placement through a single surgical incision
The Genio DREAM trial demonstrated:
- 63.5% AHI responder rate
- 71.3% oxygen desaturation index responder rate
- Median AHI reduction of 70.8%
Eligibility and Costs
Eligibility criteria for Inspire therapy include:
- Age 22 or older
- Moderate to severe sleep apnea with AHI between 15 and 65 events per hour
- BMI below 33 kg/m²
- Documented difficulty with CPAP
- Normal anterior-posterior predominant retropalatal collapse pattern on drug-induced sleep endoscopy
The procedure carries a significant financial burden, with uninsured costs ranging from $30,000 to $40,000. However, most major commercial insurers, Medicare, and Veterans Affairs provide coverage for eligible candidates.
Adverse events remain generally uncommon and mild. The most frequently reported side effects include temporary soreness at the implant site and throat discomfort, which typically resolve within weeks. Serious adverse events are rare, with only 6% of patients reporting serious device-related complications after one and five-year follow-up.
Daytime Neuromuscular Stimulation and Oral Appliances
Beyond implants and medications, several non-invasive innovations are expanding the treatment arsenal.
eXciteOSA: Training Your Tongue During the Day
eXciteOSA represents a genuinely novel approach using neuromuscular electrical stimulation delivered through a daytime device requiring just 20 minutes daily. This eliminates the need for nighttime wearables or invasive procedures.
The eXciteOSA device delivers precisely calibrated electrical stimulation to the mylohyoid and related muscles through electrodes placed inside the mouth. This activates motor nerves to strengthen and increase endurance of critical airway-stabilizing muscles.
The FDA authorized eXciteOSA for treatment of mild obstructive sleep apnea and snoring. Clinical studies demonstrated:
- 90% of users experienced snoring reduction measured objectively
- About 89% of bed partners noticed significant snoring reduction after six weeks
- 78% of patients achieved measurable reduction in sleep apnea severity on home sleep testing
The therapy is indicated only for mild sleep apnea, limiting applicability to patients with moderate or severe disease. The need for sustained daily adherence for six weeks of treatment followed by ongoing maintenance creates compliance challenges.
Modern Oral Appliances
Custom-fitted mandibular advancement devices remain a well-established alternative to CPAP with considerably improved design compared to earlier generations. These devices work by gently repositioning the mandible anteriorly during sleep, mechanically enlarging the pharyngeal airway space and reducing dynamic airway collapse.
While CPAP produces greater reductions in apnea-hypopnea index (65-70% versus 40-60% for oral appliances), the efficacy gap narrows when considering real-world adherence patterns. Research indicates that when patients select their preferred treatment after experiencing both CPAP and oral appliances, nearly 50% prefer mandibular advancement devices, with adherence rates considerably higher in those using their preferred therapy.
A 2025 systematic review analyzing 27 papers found statistically significant differences in efficacy among different appliance design categories. These findings suggest that oral appliance design influences therapeutic efficacy substantially.
Advantages of modern custom oral appliances include:
- Portability for travel
- No electricity requirements
- Lower cost compared to some alternatives
- Generally good tolerability
However, they require professional dental fitting and ongoing adjustments for optimization.
What Patients Are Really Saying
While clinical efficacy data provides crucial evidence, genuine understanding requires examining patient perspectives that often differ from provider orientations.
A study presented at the SLEEP 2025 annual meeting examined treatment preferences for obesity and sleep apnea among both patients and sleep medicine professionals. It revealed a significant gap in priorities:
- More than 75% of patients and clinicians considered CPAP and tirzepatide acceptable treatment options
- About 48% of patients preferred tirzepatide over CPAP while only 35% preferred CPAP
- Sleep medicine professionals showed the inverse pattern with 53% favoring CPAP and 26% preferring tirzepatide
- While 88% of sleep professionals supported combination CPAP and tirzepatide therapy, only 61% of patients endorsed combination approaches
This suggests patients prioritize simplification and reduced treatment burden while providers prioritize maximized efficacy through multimodal interventions.
Patient narratives reveal compelling themes about CPAP's profound disruption to daily life despite mechanical efficacy. Clinical case presentations document patients describing CPAP as a burden that "imprisoned" them despite its effectiveness, with particular emotional weight on:
- The inconvenience of traveling with bulky equipment
- Embarrassment during intimate relationships
- Disruption to sleep quality from mask discomfort
- Psychological distress of confronting lifelong device dependence
One documented case of a 50-year-old woman with moderate-to-severe sleep apnea described undergoing bariatric surgery, attempting various CPAP masks without achieving comfort, abandoning CPAP during COVID when devices were unavailable, and eventually pursuing Inspire specifically to eliminate the mask requirement. She subsequently described feeling "like myself again" and expressing gratitude at no longer requiring nightly equipment for travel.
Online patient communities reveal consistent themes. A patient describing themselves as a mouth-breather who had trialed eight different CPAP masks sought information about Inspire, expressing they were "hoping there would be something that would not require hooking up to a hose and machine." This captures a fundamental emotional burden beyond mechanical inadequacy: the psychological weight of device dependence and loss of autonomy over one's sleep environment.
Understanding the Costs and Access Barriers
Despite remarkable clinical advances, economic barriers fundamentally constrain patient access to emerging solutions.
The Inspire therapy procedure carries uninsured total costs ranging from $30,000 to $40,000 for the implant alone. While most major commercial insurers, Medicare, and Veterans Affairs provide coverage for eligible patients, the prior authorization process often involves initial denials requiring appeals, creating delays that discourage treatment pursuit.
Patient experiences reveal considerable variation. Some patients report complete coverage with minimal out-of-pocket expenses due to low deductible plans or meeting out-of-pocket maximums, while others encounter significant copays, deductible obligations, or complete denials requiring formal appeals.
Zepbound carries a list price of approximately $1,086 for a 28-day supply, translating to roughly $14,000 annually. While commercial insurance coverage exists for weight loss indication, many insurance plans hadn't updated guidelines following FDA approval for sleep apnea by early 2025, creating a coverage lag requiring appeals and physician documentation.
The manufacturer's LillyDirect patient assistance program provides reduced pricing ranging from $349 to $499 monthly for varying doses, representing significant savings but still constituting considerable financial burden for uninsured or underinsured patients.
eXciteOSA represents a more economically accessible option for mild sleep apnea, with retail pricing at $1,650 for the device, though the therapy remains limited to mild disease. Oral appliances typically cost between $1,200 and $2,000 for custom fabrication and fitting.
Economic disparities in sleep apnea treatment access contribute to documented health inequities affecting lower-income individuals, racial and ethnic minorities, individuals in rural healthcare systems, and populations with Medicaid or no insurance. The emerging innovations, while clinically transformative for those with access, risk widening health inequities if policymakers don't implement intentional strategies ensuring equitable access.
Important Questions That Remain Unanswered
Despite enthusiasm surrounding emerging treatments, substantial controversies and unresolved clinical questions merit careful examination.
Long-Term Safety and Cardiovascular Outcomes
While AD109 demonstrates impressive apnea-hypopnea index reductions in Phase 3 trials, important questions remain regarding:
- Long-term safety beyond the six-month and 12-month trial periods
- Effects on daytime symptoms beyond fatigue scales
- Cardiovascular implications of stimulant effects from atomoxetine
Sleep physicians have specifically raised concerns that atomoxetine, as a stimulant medication, may adversely affect sleep quality while improving the apnea-hypopnea index through neuromuscular augmentation. This could create a scenario where apnea events decrease but sleep architecture quality deteriorates, resulting in paradoxical daytime sleepiness persistence.
The six-month to 12-month trial durations provide insufficient evidence to understand effects on major cardiovascular events – the ultimate clinical outcome of interest in sleep apnea management. Multiple sleep medicine leaders have noted that while apnea event reduction is promising, 10-year longitudinal data regarding heart attack, stroke, and mortality would be necessary to claim true disease modification rather than surrogate marker improvement.
The Cardiovascular Benefit Controversy
A significant area of scientific debate has emerged regarding cardiovascular risk reduction rationale for aggressively treating sleep apnea in asymptomatic or minimally symptomatic patients. Traditionally, sleep medicine practitioners have argued that even asymptomatic sleep apnea warrants treatment to prevent long-term cardiovascular consequences.
However, multiple randomized controlled trials evaluating CPAP's cardiovascular outcomes have produced disappointing null results. The American Thoracic Society convened an official workshop in 2024 specifically to address "The Great Controversy of Obstructive Sleep Apnea Treatment for Cardiovascular Risk Benefit."
Workshop participants acknowledged significant limitations in existing trials, including suboptimal CPAP adherence rates biasing results toward the null hypothesis, use of composite cardiovascular outcomes that obscure effects on specific disease types, and restricted applicability to actual sleep clinic populations. The workshop concluded that while symptomatic patients with excessive daytime sleepiness clearly benefit from treatment, the evidence base for intensive treatment of asymptomatic sleep apnea remains uncertain.
This uncertainty has considerable clinical implications. If cardiovascular risk reduction cannot be reliably demonstrated in asymptomatic patients, the risk-benefit calculation for recommending Inspire implantation or tirzepatide therapy shifts significantly.
Device Reliability and Replacement
Long-term device reliability data remain limited since Inspire received FDA approval only in 2014. The device requires battery replacement approximately every 10 years, necessitating a minor outpatient surgical procedure. Legitimate questions exist about what will occur when devices approach or exceed the 11-year battery lifespan in patients implanted over a decade ago.
The Future of Sleep Apnea Treatment
The sleep apnea treatment landscape continues rapidly expanding with multiple novel approaches progressing through clinical development.
Apnimed is advancing AD109 through additional trials and preparing FDA submission in early 2026. Pharmaceutical companies and academic centers are investigating combination approaches including concurrent use of eXciteOSA and oral appliances, or integration of pharmacological and device-based therapies to optimize synergistic benefit.
Artificial intelligence and machine learning applications are beginning to enhance treatment selection, with algorithms analyzing sleep study patterns, anatomic imaging, and clinical characteristics to predict individual patient responses to different interventions. This technological progression toward precision sleep medicine promises to enhance treatment efficacy by enabling better patient stratification and treatment optimization.
The integration of wearable technology represents another frontier. In 2024, Samsung Galaxy and Apple Watches received FDA approval for sleep apnea detection features that may facilitate earlier diagnosis among patients not yet formally evaluated. Remote monitoring capabilities now embedded in Inspire V devices enable physicians to adjust settings and track therapy adherence without requiring in-person office visits.
Choosing the Right Treatment for You
The year 2025 represents a transformative period for obstructive sleep apnea treatment. The paradigm of accepting CPAP or accepting untreated sleep apnea has definitively ended.
For patients struggling with CPAP intolerance, multiple evidence-based alternatives now exist:
- Inspire V system demonstrates remarkable efficacy, durability, quality of life benefits, and sustained patient satisfaction for CPAP-intolerant patients with moderate to severe disease
- eXciteOSA provides FDA-approved daytime neuromuscular electrical stimulation for patients preferring to avoid surgery or who have mild disease
- Oral appliances remain valuable alternatives when properly designed, fitted, and adjusted by experienced dentists
The pending FDA approval of AD109 based on positive Phase 3 trial results promises to revolutionize treatment paradigms by offering sleep apnea patients a simple once-nightly oral medication addressing the root neuromuscular causes of airway collapse. This breakthrough pharmaceutical therapy, anticipated to reach clinical practice in 2026, will expand treatment accessibility considerably.
For healthcare providers, the expanded treatment options require nuanced clinical decision-making incorporating patient type, symptom burden, other health conditions, healthcare literacy, and individual values and preferences. Rather than automatically defaulting to CPAP or assuming treatment goals are purely sleep study improvement, contemporary sleep medicine practice should explicitly discuss quality of life goals, treatment burdens, and individual preferences when selecting among increasingly sophisticated options.
At The Sleep Loft, we understand that better sleep starts with finding the right mattress and sleep environment. While we don't treat medical conditions like sleep apnea, we're here to help you create the most comfortable and supportive sleep setup possible. If you're managing sleep apnea with any of these treatments, having the right mattress can make a significant difference in your overall sleep quality.
Visit us at our NYC or New Jersey showrooms to try out top-rated mattresses in person, or browse our collection online. We work with leading brands including Helix, Avocado, Brooklyn Bedding, Leesa, and Puffy to ensure you find the perfect match for your sleep needs. For those seeking enhanced comfort and customization, consider exploring our adjustable bed bases that allow you to elevate your head and feet for optimal positioning while managing sleep apnea symptoms.
Frequently Asked Questions
What is the first FDA-approved medication for sleep apnea?
Zepbound (tirzepatide) became the first FDA-approved medication specifically for obstructive sleep apnea in December 2024. It's approved for moderate to severe sleep apnea in adults with obesity, working through weight loss to reduce airway obstruction. About 50% of treated participants achieved complete remission or mild sleep apnea with resolved symptoms in clinical trials.
How does Inspire therapy work for sleep apnea?
Inspire is an implantable device that stimulates the hypoglossal nerve to activate tongue muscles during sleep, preventing airway collapse. You turn it on with a remote before bed, and it automatically delivers precisely timed electrical pulses synchronized with your breathing throughout the night. Clinical studies show a 72% success rate with sustained benefits at five-year follow-up.
What is AD109 and when will it be available?
AD109 is an investigational oral medication combining aroxybutynin and atomoxetine to address the neuromuscular causes of airway collapse. Phase 3 trials showed a 56% reduction in apnea events across all severity levels and weight classes. Apnimed plans to submit a new drug application to the FDA in early 2026, potentially making it available within 18 to 24 months.
How much does Inspire therapy cost?
Inspire therapy costs between $30,000 and $40,000 without insurance coverage. However, most major commercial insurers, Medicare, and Veterans Affairs provide coverage for eligible candidates who meet specific criteria including moderate to severe sleep apnea, BMI below 33 kg/m², and documented CPAP intolerance. Out-of-pocket costs vary based on individual insurance plans and deductible status.
Can I use sleep apnea medications instead of CPAP?
It depends on your specific situation. Tirzepatide is currently approved only for patients with moderate to severe sleep apnea who also have obesity, and it requires weeks to months to show benefit through weight loss. AD109, when approved, will work across all severity levels and weight classes with effects evident by 26 weeks. Neither medication provides the immediate benefit of CPAP, which works on the first night of use.
What are the success rates of oral appliances for sleep apnea?
Oral appliances demonstrate 40-60% efficacy in reducing apnea-hypopnea index compared to CPAP's 65-70% reduction. However, adherence rates are considerably higher for oral appliances, particularly when patients select their preferred treatment after trying both options. Nearly 50% of patients prefer mandibular advancement devices over CPAP when given the choice.
Is eXciteOSA effective for all types of sleep apnea?
eXciteOSA is FDA-authorized only for mild obstructive sleep apnea and snoring. Clinical studies showed 90% of users experienced snoring reduction and 78% achieved measurable reduction in sleep apnea severity. It's not indicated for moderate or severe sleep apnea, where more aggressive interventions like CPAP, Inspire, or medications would be more appropriate.
Who is eligible for Inspire therapy?
Eligibility criteria include:
- Age 22 or older
- Moderate to severe sleep apnea with AHI between 15 and 65 events per hour
- BMI below 33 kg/m² (though some centers may accept higher with careful selection)
- Documented inability to tolerate CPAP despite reasonable attempts
- Normal anterior-posterior predominant retropalatal collapse pattern on drug-induced sleep endoscopy
Patients with complete concentric collapse at the soft palate level are generally not candidates.
